[SALM] Whole foods

Salmon

Last updated Jul 18, 2026 · Refresh target: weekly

Is salmon good for you today?

Mostly yes. The strongest, most consistent signal is that eating oily fish like salmon is associated with lower cardiovascular and stroke risk. The main caveat is that omega-3 supplement trials have been far more equivocal than the dietary evidence, and plenty of reviews still land on 'inconsistent' — but the food-consumption ledger leans clearly favorable.

Current score

+71

Sentiment

Strongly positive

Confidence

70 / 100

Controversy

9 / 100

Settled

Evidence items

30D+1

90D+1

1Y+1

The seafood desk is long oily fish: prospective cohorts and meta-analyses repeatedly tie higher fish intake to lower coronary, stroke, and mortality risk. Short interest comes from null omega-3 supplement trials and reviewers who keep writing 'inconsistent' — but those test capsules, not dinner.

Analyst noteConfidence is fair, and deliberately not higher: the favorable signal rests on numerous prospective cohorts and meta-analyses pointing the same way, but they are observational and prone to residual socioeconomic/healthy-user confounding — people who eat salmon tend to be richer and healthier to begin with. The cleaner, confounding-free evidence (randomized omega-3 trials) is more equivocal, which is why this is not scored as a slam dunk.

Analyst note

Confidence is fair, and deliberately not higher: the favorable signal rests on numerous prospective cohorts and meta-analyses pointing the same way, but they are observational and prone to residual socioeconomic/healthy-user confounding — people who eat salmon tend to be richer and healthier to begin with. The cleaner, confounding-free evidence (randomized omega-3 trials) is more equivocal, which is why this is not scored as a slam dunk.

Last meaningful move

Jun 2022

Score move

points

Driven by

Fish and human health: an umbrella review of observational studies.

International journal of food sciences and nutrition · Jun 26, 2022 · Positive · index impact +14

This study carried one of the largest positive public impacts added to the ledger around the move.

View study ->

Evidence sentiment index

Historical price of the salmon thesis

Start

MonthYear

End

MonthYear

Latest+71

SignalStrongly positive

Confidence70 / 100

Axis fitted: -50 to +100. Index scale remains -100 to +100.

Latest studies

Evidence tape

Sorted by evidence availability date, newest first.

Did we miss a study?

FilterSort

Showing 3 of 49 studies after filter and sort.

expert commentary

Omega-3 Index: an emerging biomarker in cardiovascular prevention.

Nutricion hospitalaria · Jun 23, 2026Open study

Direction: PositiveIndex impact +3

Narrative review of the Omega-3 Index (erythrocyte EPA+DHA) as a cardiovascular biomarker: argues long-chain omega-3s are cardioprotective (index <4% linked to high risk of cardiac events/sudden death, >8% to protection) and predict all-cause mortality better than dietary questionnaires, attributing trial controversy to reliance on estimated intake. Nutrient/biomarker-level evidence, not salmon-specific.

Details and limitations

Limitations: Review full paper for confounding, population characteristics, endpoint definitions, and study design before publishing.

Evidence weight 4 / 100pubmedjournal-articledoi:10.20960/nh.06965pmid:42377354

Limitations: Review full paper for confounding, population characteristics, endpoint definitions, and study design before publishing.

Evidence weight 4 / 100pubmedjournal-articledoi:10.20960/nh.06965pmid:42377354

expert commentary

Omega-3 fatty acids in primary and secondary prevention of cardiovascular diseases.

Progress in cardiovascular diseases · Mar 27, 2024Open study

Direction: PositiveIndex impact +1

abstract suggests a mixed signal. Even with substantial progress in primary and secondary prevention, cardiovascular disease (CVD) persists as a major cause of mortality and morbidity globally.

Details and limitations

Limitations: Review full paper for confounding, population characteristics, endpoint definitions, and study design before publishing.

Evidence weight 2 / 100pubmedjournal-articlereviewdoi:10.1016/j.pcad.2024.03.009pmid:38547956

Limitations: Review full paper for confounding, population characteristics, endpoint definitions, and study design before publishing.

Evidence weight 2 / 100pubmedjournal-articlereviewdoi:10.1016/j.pcad.2024.03.009pmid:38547956

meta analysis

Circulating Docosahexaenoic Acid and Risk of All-Cause and Cause-Specific Mortality.

Mayo Clinic proceedings · Mar 20, 2024Open study

Direction: PositiveIndex impact +19

abstract suggests a favorable signal. OBJECTIVE: To assess the associations of docosahexaenoic acid (DHA), a marine omega-3 fatty acid, with long-term all-cause mortality, cardiovascular (CV) mortality, and cancer mortality.

Details and limitations

Limitations: Review full paper for confounding, population characteristics, endpoint definitions, and study design before publishing.

Evidence weight 28 / 100pubmedmeta-analysisjournal-articledoi:10.1016/j.mayocp.2023.11.026pmid:38506781

Limitations: Review full paper for confounding, population characteristics, endpoint definitions, and study design before publishing.

Evidence weight 28 / 100pubmedmeta-analysisjournal-articledoi:10.1016/j.mayocp.2023.11.026pmid:38506781

Showing 3 of 49 studies.